← AI-Native VC & PE Funds·CASE 006·HEALTHTECHMAYANK TALWAR·case file open
§ 00 ── CALM/STORM VENTURES · "MENTAL HEALTH OBJECTIVELY MEASURABLE" · €30M FUND II · MOST ACTIVE EU HEALTHTECH VC

You publish the thesis that mental health can be measured objectively. The portcos operationalize it. The EU AI Act will require it of them in 79 days. Your fund needs the same primitive — two layers, one substrate.

86 portcos · 12+ AI-native · two layers

§ 01 ── THE PATTERN

The discipline you back inside your portcos is the discipline the AI Act will require from them — and the discipline your Fund III narrative needs from you.

THE THESIS YOU PUBLISH

"Making mental health as objectively measurable as physical health."

— Thymia · calmstorm.vc/portfolio

"AI in health tech remains a major focus … massive potential to help clinicians spend more time with patients by automating administrative tasks."

— Johannes Blaschke · Coulter Partners · January 2025
WHAT'S OBSERVABLE

86 investments · €50M AuM · 9 new in last 12 months. AI-native portcos across mental health (Upheal · Thymia · Meela), chronic care (Oska · Vermut), preventive screening (Circle · Aeon), clinical workflows (Aiomics).

WHAT'S STRUCTURALLY HAPPENING

Each portco runs a different measurement regime — video biomarker · NLP · matching algorithm · audio capture · activity log · self-report. The narrative stays clean. The evidence cadence beneath each portco drifts unmeasured at fund level.

THE AI ACT WINDOW
REGIME
EFFECTIVE
RUNWAY
Article 50 transparency
2 Aug 2026
79 days
Standalone high-risk AI
2 Dec 2027
SaMD · MDR / IVDR
2 Aug 2028

Notified-body assessments already cite AI Act compliance now.

WHAT THE GAP COSTS

Portco fails AI Act technical file → CE stalls → carry exposed. Fund cannot reconstruct evidence chain behind 2025–26 decisions → Fund III narrative softens with corporate LPs (CSS · Schwabe · Raiffeisenbank).

§ 02 ── WHY THIS HAPPENS · STRUCTURALLY

The thesis is the public layer. The portco evidence regimes are the recursive layer. The substrate is the same primitive at both levels.

PARTNER · NATURAL LANGUAGE

You back Thymia for biomarker assessment, Upheal for session intelligence, Meela for therapist–patient matching, Aiomics for record structuring. Each one ships measurement-grade evidence of something previously subjective. The discipline they ship to clinicians is what the AI Act now requires from them — and what your fund needs for LPs and Fund III. One primitive. Two layers.

SUBSTRATE · TRANSLATED
AUDIT CHAIN
every Rx reading per portco hash-chained, append-only, never-deletable, with evidence mode tagged at emission [verified] [model-derived] [self-reported] [stale] [contradictory]. Runs at both layers — portco-side under AI Act review, fund-side under LP defensibility.
METHODOLOGY OVERLAY · L2 YAML
each portco's Rx, Tx, wx encoded as inspectable YAML. What Thymia operationalizes for clinicians is the same artifact the fund operates on internally — versioned, portable, replay-tested.
INSIDE THE PORTFOLIO · WHAT MEASUREMENT ACTUALLY MEANS
PORTCO
DOMAIN VARIABLE
EVIDENCE REGIME
Thymia
depression / cognitive severity
video + speech biomarker model output
Upheal
therapy session captured
audio capture · AI-extracted notes · clinician-tagged
Meela
therapist–patient match quality
matching algorithm + post-session retention
Aiomics
structured records produced
NLP extraction from unstructured EHR
Oska Health
chronic care episode
conversational AI logs + outcome signal
Vermut
senior engagement event
activity participation log

built for AI Act Article 6(1) replay

§ 03 ── A PHASE 0 PROPOSITION · TWO WEEKS · FREE · ONE PORTCO · ZERO REAL DATA

Pick one AI-native portco. We rebuild its evidence chain in synthetic. You see whether it survives AI Act Article 6(1) replay or doesn't.

Phase 0 is not a pilot. Two-week structural diagnostic against one portco of your choice — synthetic data only, no production access required. The question it answers is narrow and load-bearing: under AI Act high-risk replay across two methodology versions, does this portco's evidence regime hold — and does your investment thesis evidence chain hold beneath it? Three artifacts come out the other side. You keep all three whether you continue or not.

THE DIAGNOSTIC · WHAT TWO WEEKS PRODUCES

  1. 01
    Methodology overlay v0.1

    The portco's R_x, T_x, w_x encoded as L2 YAML — evidence regime made inspectable. Versioned. Portable. Runs in your environment without us.

  2. 02
    Audit chain replay

    The chain populated against synthetic Rₓ readings across two methodology versions — Article 6(1) replay simulated before notified-body assessment starts citing it. Drift visible or not.

  3. 03
    Cost model

    Framed against AI Act technical-file timing, Fund III LP-defensibility, and corporate LP follow-on cadence (CSS · Schwabe · Raiffeisenbank). Risks named. What Phase 1 costs. Where this approach breaks.

↓ LIVE · INTERROGATE THE CASE
§ 04 ── THE MOST LOAD-BEARING SECTION

Pressure-test the substrate. Ask where it breaks.

The substrate answers in its own voice — the same primitive we'd install on one of your portcos. Not a demo. The actual reasoning surface.

STREAMING · κ ≥ 0.85 · ANONYMITY HOLDS · CITATIONS BY DEFAULT

↵ to send · ⇧↵ for newline
first-principles probes:
§ END ── THE NEXT STEP

If the pattern reads true, the next step is to test whether one AI-native portco is the right Phase 0 target.

If relevant, I can send a short async questionnaire — no call needed — and build a no-charge synthetic-data Phase 0 PoC "Calm/Storm AI OS". Within two weeks, replay one AI-native portco's evidence chain against Article 6(1) before the notified bodies start citing it.